Financial Performance - Operating income reached CNY 26,203.50 million, a year-on-year increase of 155.93%[5] - Net profit attributable to shareholders was CNY 7,936.30 million, up 232.18% year-on-year[5] - The basic earnings per share increased by 147.50% to CNY 0.99[5] - The company's operating revenue for Q1 2021 reached RMB 26,203.50 million, a significant increase of 155.93% compared to RMB 10,238.41 million in the same period last year[15] - The company's profit before tax saw a substantial rise, leading to income tax expenses of RMB 1,294.30 million, up 408.21% from RMB 254.68 million in the previous year[16] - Operating profit for Q1 2021 was ¥92,407,444.53, up from ¥26,740,319.71 in Q1 2020, representing a growth of 245.5%[29] - Net profit for Q1 2021 was ¥79,363,027.05, compared to ¥23,891,296.23 in Q1 2020, marking an increase of 231.5%[30] - The total profit for Q1 2021 was ¥92,306,044.77, compared to ¥26,438,092.74 in Q1 2020, an increase of 249.5%[29] Cash Flow - Net cash flow from operating activities surged by 477.67% to CNY 7,496.84 million[5] - The net cash flow from operating activities for Q1 2021 was ¥74,968,444.93, up from ¥12,977,822.01 in Q1 2020, representing a growth of 478%[35] - The cash inflow from operating activities totaled ¥291,695,126.78 in Q1 2021, compared to ¥117,729,264.36 in Q1 2020, reflecting a growth of 147%[35] - The company reported a net increase in cash and cash equivalents of ¥30,515,315.59 in Q1 2021, contrasting with a decrease of -¥69,425,330.57 in Q1 2020[36] Assets and Liabilities - Total assets increased by 8.63% to CNY 149,436.63 million compared to the end of the previous year[5] - The total liabilities increased significantly, with contract liabilities rising by 91.38% to RMB 5,858.98 million due to increased sales[14] - Current liabilities rose to CNY 346,887,237.31, compared to CNY 163,324,507.84 in the previous period, indicating a significant increase of about 112.5%[21] - The total liabilities increased to CNY 350,964,243.26 from CNY 167,737,235.03, reflecting a growth of approximately 109.0%[21] - The total assets as of March 31, 2021, amounted to RMB 1,141,863,175.16, compared to RMB 1,047,376,755.51 at the end of 2020[19] Shareholder Information - The number of shareholders reached 11,843 at the end of the reporting period[11] - The top shareholder, Shi Huiyong, holds 52.50% of the shares, totaling 42,000,000 shares[11] Research and Development - The company's R&D expenses increased by 140.48% to RMB 1,109.84 million, indicating a focus on innovation and product development[15] - Research and development expenses in Q1 2021 amounted to ¥11,098,409.42, which is 140.5% higher than ¥4,615,119.03 in Q1 2020[31] Inventory and Accounts Receivable - Inventory rose by 44.67% to RMB 9,712.33 million, driven by the increase in sales volume[14] - Accounts receivable financing increased by 54.45% to RMB 1,443.87 million, attributed to increased sales and more bank acceptance bills received[14] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[13]

浙江拱东医疗器械股份有限公司 2020 年年度报告 公司代码：605369 公司简称：拱东医疗 浙江拱东医疗器械股份有限公司 2020 年年度报告 1/207 浙江拱东医疗器械股份有限公司 2020 年年度报告 重要提示 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人施慧勇、主管会计工作负责人潘磊及会计机构负责人（会计主管人员）程菊文声 明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2020年度利润分配预案为： 1、公司拟向全体股东每10股派发现金红利18.00元（含税）。截至2020年12月31日，公司总 股本8,000.00万股，以此计算合计拟派发现金红利14,400.00万元（含税），占合并报表中归属于母 公司股东净利润的63.75%，剩余未分配利润结转至下一年度。 2、公司拟向全体股东以资本公积金转增股本方式每10股转增4股。截至2020年12月31日，公 司总股本8,000.00万股，本次转股后，公司的总股本为11,200.00万股。 3、如在本利润分配预案披露之日起至实施权益分派股权 ...

| 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 浙江拱东医疗器械股份有限公司 2020 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 浙江拱东医疗器械股份有限公司 2020 年第三季度报告 公司代码：605369 公司简称：拱东医疗 浙江拱东医疗器械股份有限公司 2020 年第三季度报告 1 / 26 3 / 26 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上 年度末增减(%) 总资产 1,281,682,286.09 536,041,068.14 139.10 归属于上市公司股东的净资产 1,141,707,336.77 405,248,147.50 181.73 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减 (%) 经营活动产生的现金流量净额 160,340,651.45 74,445,769.52 115.38 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年 ...